SpringWorks Therapeutics SWTX 深 滬
等待開盤 07-18 09:30:00 美东时间
46.99
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 46.99
- 總市值 35.41亿
- 52周最高 62.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 28.21
- 委 比 0.00%
- 總股本 7534.90万
- 歷史最高 96.48
- 量 比 0
- 振 幅 0.00%
- 歷史最低 13.60
- 每 手 1
- 風險率 7.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Madrigal gains after Rezdiffra patent win
Madrigal Pharmaceuticals (NASDAQ:MDGL) traded higher in the premarket on Wednesday after the company announced a patent win related to its lead asset, Rezdiffra, approved by the FDA in 2024 for a live...
07-16 20:54
California Rep. Gilbert Ray Cisneros Sold Over $28K Worth of SpringWorks Therapeutics Inc Ordinary Shares Stock: Here's What You Should Know
An official report on July 10, 2025 reveals Representative Gilbert Ray Cisneros...
07-11 23:00
SpringWorks Therapeutics Completes Merger and Delisting
Springworks Therapeutics ( ($SWTX) ) just unveiled an update. SpringWorks Thera...
07-01 21:08
SpringWorks Merger with Merck Approved by Shareholders
Springworks Therapeutics ( ($SWTX) ) has shared an announcement. On June 26, 20...
06-27 04:53
Madrigal, Viking among notable gainers after Altimmune’s MASH setback
Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as Altimmune (NASDAQ:ALT) boosted its rivals after posting a mixed outcome from a mi...
06-27 03:42
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
The European Medicines Agency (EMA) has recommended the approval of nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with progressing desmoid tumors in Europe. The European Commission (EC) is expected to make a final decision by the third quarter of 2025. Nirogacestat has already been approved in the U.S. and demonstrated significant benefits in the Phase 3 DeFi trial, including improved progression-free survival and p...
06-20 12:00
SpringWorks Therapeutics Announces Merger with Merck KGaA
An announcement from Springworks Therapeutics ( ($SWTX) ) is now available. On ...
06-16 18:49
SpringWorks gets EU endorsement for genetic disorder treatment
SpringWorks Therapeutics (NASDAQ:SWTX) said that an advisory panel of the European Medicines Agency (EMA), endorsed Mirdametinib, as a treatment for patients with neurofibromatosis type 1, aged 2 year...
05-23 21:47
SpringWorks Therapeutics Secures EMA CHMP Endorsement For Conditional Approval Of Mirdametinib In NF1-PN Treatment
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –– Decision from European Commission expected in the
05-23 20:04
